Oncolytic viruses are therapeutic agents used for in situ immunization in cancer immunotherapy. Unfortunately, its efficacy is particularly limited in solid tumors expressing stimulator of interferon ...

This flaw has prompted scientists to seek alternative solutions. One alternative to antibiotics is phage therapy, which harnesses viruses to attack bacterial cells. Conceived over a century ago ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into ...

PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company (“PHAXIAM” or “the Company”) developing innovative ...

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer. Delytact ...

Other proteins such as H-Ras and Rac1 have been shown to mediate oncolytic specificity in certain systems. The NDV genome allows for stable expression of foreign genes while avoiding the problem ...

Thibaut du Fayet, Chief Executive Officer of PHAXIAM, stated: “We start 2025 with a clear ambition to position PHAXIAM as a Specialty Pharma in Critical care, in the booming phage therapy market.